WO2014096418A3 - Micrornas as therapeutics and biomarkers for epilepsy - Google Patents

Micrornas as therapeutics and biomarkers for epilepsy Download PDF

Info

Publication number
WO2014096418A3
WO2014096418A3 PCT/EP2013/077836 EP2013077836W WO2014096418A3 WO 2014096418 A3 WO2014096418 A3 WO 2014096418A3 EP 2013077836 W EP2013077836 W EP 2013077836W WO 2014096418 A3 WO2014096418 A3 WO 2014096418A3
Authority
WO
WIPO (PCT)
Prior art keywords
epilepsy
monitoring
biomarkers
prognosticating
graduating
Prior art date
Application number
PCT/EP2013/077836
Other languages
French (fr)
Other versions
WO2014096418A2 (en
Inventor
Bénédicte DANIS
Patrik FOERCH
Rafal M. KAMINSKI
Anita KRETSCHMANN
Franziska SIEGEL
Alexander Pfeifer
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of WO2014096418A2 publication Critical patent/WO2014096418A2/en
Publication of WO2014096418A3 publication Critical patent/WO2014096418A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The present invention relates to a pharmaceutical composition for use in the treatment or prevention of epilepsy, comprising a means for alleviating or reversing the effect of a dysregulation of a miRNA molecule. The invention further relates to a vaccine for use in the treatment or prevention of epilepsy, to a biomarker or group of biomarkers associated with epilepsy, a composition for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or a predisposition for epilepsy, a method or assay for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or a predisposition for epilepsy. Also envisaged is a method for monitoring epilepsy therapy, a method of identifying an individual eligible for an epilepsy therapy, a corresponding diagnostic kit and the use of a biomarker or a group of biomarkers for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or for identifying pharmaceutically active agents useful in the treatment or prevention of epilepsy.
PCT/EP2013/077836 2012-12-21 2013-12-20 Micrornas as therapeutics and biomarkers for epilepsy WO2014096418A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1223244.3A GB201223244D0 (en) 2012-12-21 2012-12-21 Micrornas as therapeutics and biomarkers for epilepsy
GB1223244.3 2012-12-21

Publications (2)

Publication Number Publication Date
WO2014096418A2 WO2014096418A2 (en) 2014-06-26
WO2014096418A3 true WO2014096418A3 (en) 2014-08-14

Family

ID=47682463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/077836 WO2014096418A2 (en) 2012-12-21 2013-12-20 Micrornas as therapeutics and biomarkers for epilepsy

Country Status (2)

Country Link
GB (1) GB201223244D0 (en)
WO (1) WO2014096418A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066034A1 (en) 2013-10-28 2015-05-07 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
US20180327845A1 (en) * 2015-11-18 2018-11-15 Dignity Health Methods of diagnosing epilepsy
WO2018017865A1 (en) * 2016-07-20 2018-01-25 Thomas Jefferson University Inhibiting microrna to prevent development of essential hypertension
CN108403711B (en) * 2017-02-10 2020-07-31 中国科学院上海营养与健康研究所 MicroRNA for detecting and treating inflammatory bowel disease
EP3673065A4 (en) * 2017-08-25 2021-05-26 The Governing Council of the University of Toronto Compositions and methods for detecting and treating insulin resistance
US11497762B2 (en) 2017-11-03 2022-11-15 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
CA3084985A1 (en) 2017-12-06 2019-06-13 Ovid Therapeutics Inc. Use of mir101 or mir128 in the treatment of seizure disorders
US11225661B2 (en) * 2018-03-08 2022-01-18 Uriah Bekenstein Methods for controlling seizures by manipulating the levels of microRNA-211 (miR-211) in the brain
CA3139919A1 (en) * 2019-03-11 2020-09-17 Ochsner Health System Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
CN111218530B (en) * 2020-03-19 2023-10-31 广西壮族自治区水产科学研究院 Primer group and kit for detecting octopoda iridovirus 1 by fluorescence quantitative PCR
EP4155402A1 (en) * 2021-09-22 2023-03-29 Royal College of Surgeons in Ireland Modulation of microrna-335 for the treatment of sodium channelopathies
CN114410765A (en) * 2022-01-17 2022-04-29 上海大学 Application of miRNA molecular marker in schizophrenia detection
WO2024008950A1 (en) * 2022-07-08 2024-01-11 Ospedale San Raffaele S.R.L. Transgene cassettes
CN116763809B (en) * 2023-05-31 2024-01-26 广东医科大学附属医院 Application of miR-376b-3p inhibitor in preparation of epilepsy treatment drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149354A1 (en) * 2010-05-28 2011-12-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Mirnas involved in the blood brain barrier function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149354A1 (en) * 2010-05-28 2011-12-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Mirnas involved in the blood brain barrier function

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ANNE A KAN ET AL: "Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 69, no. 18, 26 April 2012 (2012-04-26), pages 3127 - 3145, XP035103746, ISSN: 1420-9071, DOI: 10.1007/S00018-012-0992-7 *
DANYELLA B. DOGINI ET AL: "MicroRNA expression profile in epilepsy: breaking molecular barriers", JOURNAL OF EPILEPSY AND CLINICAL NEUROPHYSIOLOGY, vol. 18, no. 2, 1 June 2012 (2012-06-01), pages 57 - 59, XP055113109, ISSN: 1676-2649, DOI: 10.1590/S1676-26492012000200008 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 18 July 2009 (2009-07-18), MA Z -L ET AL: "Differential expression profile of microRNAs in the different stages of hepatitis B virus infection-related hepatocarcinogenesis", XP002723254, Database accession no. EMB-2009514716 *
E. ARONICA ET AL: "Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 31, no. 6, 1 March 2010 (2010-03-01), pages 1100 - 1107, XP055113197, ISSN: 0953-816X, DOI: 10.1111/j.1460-9568.2010.07122.x *
EVA M JIMENEZ-MATEOS ET AL: "Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects", NATURE MEDICINE, vol. 18, no. 7, 1 January 2012 (2012-01-01), pages 1087 - 1094, XP055049682, ISSN: 1078-8956, DOI: 10.1038/nm.2834 *
EVA M. JIMENEZ-MATEOS ET AL: "miRNA Expression Profile after Status Epilepticus and Hippocampal Neuroprotection by Targeting miR-132", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 179, no. 5, 23 September 2011 (2011-09-23), pages 2519 - 2532, XP055113107, ISSN: 0002-9440, DOI: 10.1016/j.ajpath.2011.07.036 *
HU K ET AL: "Expression profile of microRNAs in rat hippocampus following lithium-pilocarpine-induced status epilepticus", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 488, no. 3, 25 January 2011 (2011-01-25), pages 252 - 257, XP027586171, ISSN: 0304-3940, [retrieved on 20110105] *
JAMIE TALAN: "Silencing MicroRNAs Found to Reduce Seizures in Epilepsy Model: A Potential New Route for Drug Development", NEUROLOGY TODAY, vol. 12, no. 15, 2 August 2012 (2012-08-02), pages 19 - 20, XP055113189, DOI: 10.1097/01.NT.0000418594.81081.f5 *
KAI HU ET AL: "MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus", BMC NEUROSCIENCE, BIOMED CENTRAL, LONDON, GB, vol. 13, no. 1, 22 September 2012 (2012-09-22), pages 115, XP021106819, ISSN: 1471-2202, DOI: 10.1186/1471-2202-13-115 *
P. BREST ET AL: "MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells", ENDOCRINE RELATED CANCER, vol. 18, no. 6, 26 September 2011 (2011-09-26), pages 711 - 719, XP055113699, ISSN: 1351-0088, DOI: 10.1530/ERC-10-0257 *
ROSS C. MCKIERNAN ET AL: "Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death", EXPERIMENTAL NEUROLOGY, vol. 237, no. 2, 1 October 2012 (2012-10-01), pages 346 - 354, XP055049687, ISSN: 0014-4886, DOI: 10.1016/j.expneurol.2012.06.029 *
ROSS C. MCKIERNAN ET AL: "Reduced Mature MicroRNA Levels in Association with Dicer Loss in Human Temporal Lobe Epilepsy with Hippocampal Sclerosis", PLOS ONE, vol. 7, no. 5, 15 May 2012 (2012-05-15), pages e35921, XP055113226, DOI: 10.1371/journal.pone.0035921 *
RYO OGAWA ET AL: "Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR", MEDICAL MOLECULAR MORPHOLOGY, SPRINGER-VERLAG, TO, vol. 42, no. 2, 18 June 2009 (2009-06-18), pages 102 - 109, XP019724134, ISSN: 1860-1499 *
S. ZONGARO ET AL: "The 3' UTR of FMR1 mRNA is a target of miR-101, miR-129-5p and miR-221: implications for the molecular pathology of FXTAS at the synapse", HUMAN MOLECULAR GENETICS, vol. 22, no. 10, 5 February 2013 (2013-02-05), pages 1971 - 1982, XP055113690, ISSN: 0964-6906, DOI: 10.1093/hmg/ddt044 *
WORLD CHINESE JOURNAL OF DIGESTOLOGY 20090718 WCJ PRESS CHN, vol. 17, no. 20, 18 July 2009 (2009-07-18), pages 2112 - 2116, ISSN: 1009-3079 *

Also Published As

Publication number Publication date
GB201223244D0 (en) 2013-02-06
WO2014096418A2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
WO2014096418A3 (en) Micrornas as therapeutics and biomarkers for epilepsy
IL254062B (en) Kits comprising anti-ptk7 antibody and use thereof in treating, detecting, diagnosing, or monitoring cancer
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
AR090339A1 (en) METHODS OF FORECAST, DIAGNOSIS AND TREATMENT OF IDIOPATIC PULMONARY FIBROSIS
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2015061634A3 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
MX2016002987A (en) Gene expression biomarkers of laquinimod responsiveness.
WO2014007620A3 (en) Oligonucleotide for the treatment of muscular dystrophy patients
EP2825669A4 (en) Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
WO2014043289A3 (en) Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
WO2014058976A3 (en) Biomarkers predictive for clinical response for glatiramer acetate
WO2012078558A3 (en) microRNAs AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY
WO2012012704A3 (en) Methods of detecting kidney-associated diseases or conditions
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
WO2012012714A3 (en) Methods of detecting neurological or neuropsychiatric diseases or conditions
WO2015012541A3 (en) Kit for early diagnosis of alzheimer's dementia
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
EP2723866A4 (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
WO2012142300A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
WO2013158970A3 (en) Aminosteroids for the treatment of a ptp1b associated disease
WO2012012709A3 (en) Methods of detecting cardiovascular diseases or conditions
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
BR112014001979A2 (en) use of antibody i-3859 for cancer detection and diagnosis
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13814154

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13814154

Country of ref document: EP

Kind code of ref document: A2